Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
108 participants
INTERVENTIONAL
2012-06-30
2017-04-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to examine the effects of methylphenidate on the cognitive functions in healthy individuals when performing fatiguing cognitive tasks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Evaluation of Neurofeedback Efficacy in Adults With ADHD
NCT01852357
Behavioral Intervention for Children With Attention Deficit Hyperactivity Disorder(ADHD)
NCT02327585
Motivated Behavior in Adults With and Without ADHD
NCT02630017
The Effect of Modafinil on Affective and Cognitive Processing
NCT03426202
Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT01238822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to recruit 120 total healthy participants. Overall Safety Plan Subject Protections and Safety Monitoring
1. Confidentiality of records is assured by assigning the subjects research numbers and storing computer files without reference to name, except for a single linking file that links subject's names with their research numbers. Paper records are kept in locked file drawers in a locked room, to which only authorized research personnel have access. When the study is completed, the linking file that links subject's names with their research numbers will be permanently destroyed.
2. Furthermore, upon the event of a subject's participation being terminated, all information collected prior to the subject being removed from the study, will be destroyed.
3. Personnel involved in the study are acutely sensitive to people's unease about revealing personal information. Research personnel also take the required Program for Education and Evaluation in Responsible Research and Scholarship certification, and take the utmost precautions about protecting confidentiality. When potential subject voices their lack of interest in participating, all identifying information is destroyed. During the study, subjects are reminded that they do not have to answer questions that make them feel uncomfortable
i. Data Safety and Monitoring Plan
1. No subjects will be recruited or run until the protocol receives full review and approval by the Medical IRB at the University of Michigan. A clinical research associate will accompany all subjects throughout the study. Any minor anxiety arising during the course of the procedures will be immediately assessed, and typically managed with reassurance and simple relaxation techniques. Assessment will always include an evaluation of the subject's ability to continue in the protocol.
2. All subjects will be fully informed of all the possible side-effects that could be encountered during the study. Every measure will be taken to protect subjects against even the rarest possible side effects. Principal Investigator, Dr. Chandra Sripada, has extensive prior experience with methylphenidate and the challenges utilized in this study.
3. Subjects will be encouraged to contact the investigator if they notice any symptoms or untoward side effects. All subjects will have direct access to the phone numbers and pagers of the study coordinator and the responsible physician (Dr. Sripada), as well as a 24-hour contact number (emergency room services). This information is included in the copy of the consent forms provided to the subjects.
ii. Reporting of adverse events
Adverse events (AEs) will be recorded and tracked for these projects. Adverse events will be reported per IRBs, FDA, and NIH guidelines. An adverse event is any experience that has taken place during the course of a research project, which, in the opinion of the investigators, was harmful to a subject participating in the research, increased the risks of harm in the research, or had an unfavorable impact on the risk/benefit ratio. Adverse events will be graded using the mild, moderate, severe terminology as defined:
* Mild - Noticeable to the subject, does not interfere with the subject's daily activities, usually does not require additional therapy, dose reduction, or discontinuation of the study.
* Moderate - Interferes with the subject's daily activities, possibly requires additional therapy, but does not require discontinuation of the study.
* Severe - Severely limits the subject's daily activities and may require discontinuation of the study. This would include all adverse events defined as "Serious" by the IRBMED.
The PI will assign attribution as definitely associated, probably associated, possibly associated, or unrelated. Adverse events will also be recorded as expected or unexpected. All Serious AEs and/or unexpected AEs will be reported to the IRB, NIH, and the FDA, within 7 days of occurrence or recognition. Fatal or life-threatening adverse events will be reported to the above institutions within 24 hours. Regular annual reviews of protocol activity and all adverse events will be submitted to the IRBs and NIH. Other less serious and expected AEs will also be reported to the above institutions with compliance to their requirements.
iii. Persons responsible Chandra Sekhar Sripada and Project Coordinator Christina Bohensky will be responsible for overseeing data integrity, safety monitoring, and reporting of adverse events. During the phone conferences and semi -annual meetings adverse events, recruitment, data quality and integrity and compliance with protocols will be discussed as well.
VI. Data Analysis Regression analysis will be utilized to assess whether the dependent measures for the tasks (accuracy, reaction time) are significantly correlated with measures of trait impulsivity derived from the Barratt Impulsivity Scale-11 questionnaire. Independent samples t-tests will be used to determine whether task performance differs due to methylphenidate versus placebo administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Easy
Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
Placebo
20 mgs of methylphenidate or a placebo to be administered one hour before task performance
Easy Behavioral Task
Subjects do an easy version of the Letter E Task.
Placebo Hard
Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
Placebo
20 mgs of methylphenidate or a placebo to be administered one hour before task performance
Hard Behavioral Task
Subjects do a hard version of the Letter E Task.
Methylphenidate Easy
Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
Methylphenidate
20 mgs of methylphenidate or placebo to be administered one hour before task performance
Easy Behavioral Task
Subjects do an easy version of the Letter E Task.
Methylphenidate Hard
Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
Methylphenidate
20 mgs of methylphenidate or placebo to be administered one hour before task performance
Hard Behavioral Task
Subjects do a hard version of the Letter E Task.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylphenidate
20 mgs of methylphenidate or placebo to be administered one hour before task performance
Placebo
20 mgs of methylphenidate or a placebo to be administered one hour before task performance
Easy Behavioral Task
Subjects do an easy version of the Letter E Task.
Hard Behavioral Task
Subjects do a hard version of the Letter E Task.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any clinically significant medical condition
* Currently taking any medications (i.e., decongestants)
* Currently taking any psychoactive medications
* Alcohol or substance abuse (current or in the past 2 years)
* Liver or Kidney disease
* Any clinically significant personal or family history of cardiac problems
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chandra Sekhar Sripada
Assistant Professor of Psychiatry, Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chandra Sekhar Sripada, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rachel Upjohn Building, East Medical Campus
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.